XUP Fundamental Analysis - GENFIT

Fundamental Rating

Taking everything into account, XUP scores 2 out of 10 in our fundamental rating. XUP was compared to 81 industry peers in the Biotechnology industry. While XUP seems to be doing ok healthwise, there are quite some concerns on its profitability. XUP does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

XUP had negative earnings in the past year.

In the past year XUP has reported a negative cash flow from operations.

The reported net income has been mixed in the past 5 years: XUP reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: XUP reported negative operating cash flow in multiple years.

1.2 Ratios

XUP's Return On Assets of -17.95% is in line compared to the rest of the industry. XUP outperforms 55.42% of its industry peers.

XUP's Return On Equity of -74.92% is in line compared to the rest of the industry. XUP outperforms 50.60% of its industry peers.

		Industry Rank	Sector Rank
ROA	-17.95%
ROE	-74.92%
ROIC	N/A

ROA(3y)-8.89%

ROA(5y)-10.75%

ROE(3y)-21.85%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

XUP's Profit Margin has declined in the last couple of years.

In the last couple of years the Operating Margin of XUP has declined.

XUP has a Gross Margin of 95.42%. This is amongst the best in the industry. XUP outperforms 93.98% of its industry peers.

XUP's Gross Margin has been stable in the last couple of years.

XUP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	95.42%

OM growth 3Y-50.61%

OM growth 5YN/A

PM growth 3Y-69.97%

PM growth 5YN/A

GM growth 3Y-0.4%

GM growth 5Y0.52%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XUP does not have a ROIC to compare to the WACC, probably because it is not profitable.

XUP has about the same amout of shares outstanding than it did 1 year ago.

XUP has more shares outstanding than it did 5 years ago.

The debt/assets ratio for XUP is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -1.24, we must say that XUP is in the distress zone and has some risk of bankruptcy.

XUP's Altman-Z score of -1.24 is on the low side compared to the rest of the industry. XUP is outperformed by 60.24% of its industry peers.

A Debt/Equity ratio of 0.09 indicates that XUP is not too dependend on debt financing.

XUP's Debt to Equity ratio of 0.09 is in line compared to the rest of the industry. XUP outperforms 57.83% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Altman-Z	-1.24

ROIC/WACCN/A

WACC7.26%

2.3 Liquidity

A Current Ratio of 3.69 indicates that XUP has no problem at all paying its short term obligations.

With a decent Current ratio value of 3.69, XUP is doing good in the industry, outperforming 66.27% of the companies in the same industry.

XUP has a Quick Ratio of 3.69. This indicates that XUP is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 3.69, XUP is doing good in the industry, outperforming 71.08% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.69
Quick Ratio	3.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

XUP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -289.19%.

The earnings per share for XUP have been decreasing by -70.84% on average. This is quite bad

The Revenue for XUP has decreased by -45.94% in the past year. This is quite bad

The Revenue has been growing by 11.61% on average over the past years. This is quite good.

EPS 1Y (TTM)-289.19%

EPS 3Y-70.84%

EPS 5YN/A

EPS Q2Q%-137.74%

Revenue 1Y (TTM)-45.94%

Revenue growth 3Y-6.06%

Revenue growth 5Y11.61%

Sales Q2Q%-45.28%

3.2 Future

The Earnings Per Share is expected to decrease by -29.44% on average over the next years. This is quite bad

Based on estimates for the next years, XUP will show a decrease in Revenue. The Revenue will decrease by -1.86% on average per year.

EPS Next Y-192.65%

EPS Next 2Y-97.6%

EPS Next 3Y-36.76%

EPS Next 5Y-29.44%

Revenue Next Year-34.41%

Revenue Next 2Y-21.78%

Revenue Next 3Y-8%

Revenue Next 5Y-1.86%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XUP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XUP. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

XUP's earnings are expected to decrease with -36.77% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-97.6%

EPS Next 3Y-36.76%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

XUP does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENFIT

FRA:XUP (12/11/2025, 7:00:00 PM)

5.1

+0.09 (+1.9%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-20 2025-11-20

Earnings (Next)04-22 2026-04-22/amc

Inst Owners0.73%

Inst Owner ChangeN/A

Ins Owners0.18%

Ins Owner ChangeN/A

Market Cap255.01M

Revenue(TTM)45.41M

Net Income(TTM)-38.96M

Analysts90.77

Price Target9.03 (77.06%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-766.16%

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-28.49%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5.62
P/FCF	N/A
P/OCF	N/A
P/B	4.81
P/tB	85
EV/EBITDA	N/A

EPS(TTM)-0.7

EYN/A

EPS(NY)-0.7

Fwd EYN/A

FCF(TTM)-0.13

FCFYN/A

OCF(TTM)-0.06

OCFYN/A

SpS0.91

BVpS1.06

TBVpS0.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-17.95%
ROE	-74.92%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	95.42%
FCFM	N/A

ROA(3y)-8.89%

ROA(5y)-10.75%

ROE(3y)-21.85%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3Y-50.61%

OM growth 5YN/A

PM growth 3Y-69.97%

PM growth 5YN/A

GM growth 3Y-0.4%

GM growth 5Y0.52%

F-Score2

Asset Turnover0.21

Health

		Industry Rank	Sector Rank
Debt/Equity	0.09
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	188.14%
Cap/Sales	7.33%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.69
Quick Ratio	3.69
Altman-Z	-1.24

F-Score2

WACC7.26%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-289.19%

EPS 3Y-70.84%

EPS 5YN/A

EPS Q2Q%-137.74%

EPS Next Y-192.65%

EPS Next 2Y-97.6%

EPS Next 3Y-36.76%

EPS Next 5Y-29.44%

Revenue 1Y (TTM)-45.94%

Revenue growth 3Y-6.06%

Revenue growth 5Y11.61%

Sales Q2Q%-45.28%

Revenue Next Year-34.41%

Revenue Next 2Y-21.78%

Revenue Next 3Y-8%

Revenue Next 5Y-1.86%

EBIT growth 1Y-217.1%

EBIT growth 3Y-53.61%

EBIT growth 5YN/A

EBIT Next Year-284.52%

EBIT Next 3Y-33.99%

EBIT Next 5YN/A

FCF growth 1Y87.94%

FCF growth 3Y-46.73%

FCF growth 5YN/A

OCF growth 1Y94.06%

OCF growth 3Y-45.7%

OCF growth 5YN/A

GENFIT / XUP.DE FAQ

What is the fundamental rating for XUP stock?

ChartMill assigns a fundamental rating of 2 / 10 to XUP.DE.

What is the valuation status for XUP stock?

ChartMill assigns a valuation rating of 0 / 10 to GENFIT (XUP.DE). This can be considered as Overvalued.

How profitable is GENFIT (XUP.DE) stock?

GENFIT (XUP.DE) has a profitability rating of 2 / 10.

Can you provide the expected EPS growth for XUP stock?

The Earnings per Share (EPS) of GENFIT (XUP.DE) is expected to decline by -192.65% in the next year.

GENFIT (XUP.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

GENFIT / XUP.DE FAQ

What is the fundamental rating for XUP stock?

What is the valuation status for XUP stock?

How profitable is GENFIT (XUP.DE) stock?

Can you provide the expected EPS growth for XUP stock?